-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2013 to Q3 2024.
- Lineage Cell Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000.
- Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.8M.
- Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
- Lineage Cell Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2020 was -$1.24M.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)